Early Lung Cancer Diagnosis in HIV Infected Population With an Important Smoking History With Low Dose CT: a Pilot Study (EP48 HIV CHEST)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01207986 |
Recruitment Status
:
Completed
First Posted
: September 23, 2010
Last Update Posted
: July 20, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hiv Infection Lung Cancer | Radiation: Low dose computed tomography (CT) | Not Applicable |
Background Epidemiological studies in France and in the western world have shown that lung cancers are the first cause of mortality amongst the non-AIDS classifying cancers in HIV-infected individuals, despite the introduction of combination antiretroviral therapies. Compared to the general population, there is an increased risk of lung cancer in HIV-infected individuals, even after adjustment on smoking and age, estimated to be around 2.6 compared to the general population. Outcomes are dismal, as diagnoses in HIV-infected individuals are usually made at very advanced stages (usually stage III or IV) without screening. Two non-randomized studies of CT-screening in a non HIV-infected population exposed to smoking have shown an important rate of early lung cancer detection and a high level of survival at 5 or 10 years. Despite a probable high prevalence of lung cancer in the HIV-infected population, no lung cancer screening or early diagnosis studies have been realised, and the prevalence is yet to be determined. We deduced from different studies of non HIV-infected populations a 3% prevalence in the HIV-infected population.
Methods Prospective multicentric and national study evaluating the prevalence of lung cancers through low-dose CT of 450 individuals with a known HIV-infection, with a nadir level of TCD4 cells < 350/µl, ≥ 40 years old and with a smoking history ≥ 20 packs a year (either active or with <3 years of weaning). CT interpretations and lung biopsies are guided by a suggested workup algorithm, which is not imposed in each HIV-caring centre.
Inclusion and follow up period Inclusion period will be 9 months, followed, in case of the discovery of a small nodule, by a CT follow up scheme of up to two years from first diagnosis. The study closes after 26 months of follow up.
Awaited results For the first time, this prospective study of lung cancers will estimate the prevalence of these cancers screened in the HIV-infected population. Risks associated with the incidence of this cancer will be investigated, including potential immune factors. An increased number of stage I non small cell lung cancers are expected.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 450 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Screening |
Official Title: | Early Lung Cancer Diagnosis in HIV Infected Population With an Important Smoking History With Low Dose CT: a Pilot Study |
Study Start Date : | February 2011 |
Actual Primary Completion Date : | June 2012 |
Actual Study Completion Date : | August 2014 |

Arm | Intervention/treatment |
---|---|
CT screening
CT interpretations and lung biopsies are guided by a suggested workup algorithm, which is not imposed in each HIV-caring centre
|
Radiation: Low dose computed tomography (CT) |
- the prevalence of lung cancers detected by lowdose computed tomography [ Time Frame: Month 0 ]
- the types of lung cancers in this population, [ Time Frame: Month 1 Month 3 Month 12 Month 24 Month 26 ]
- the staging of non small cell lung cancers, [ Time Frame: Month 1 Month 3 Month 12 Month 24 Month 26 ]
- description of risk factors for all lung cancers, [ Time Frame: Month 1 Month 3 Month 12 Month 24 Month 26 ]
- number of complications of diagnosis procedures during study [ Time Frame: Month 1 Month 3 Month 12 Month 24 Month 26 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years to 85 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥ 40 years
- able to give written consent
- HIV positive serology
- Covered by French Social Security
- Nadir L TCD4 < 350/µl
- Rate of LTCD4 > 100/µl at inclusion
- Addiction to smoking > 20 packages years, active person or deprived since < 3 years
Exclusion Criteria:
- patients who suffered from comorbidity
- unaffiliated to the social healthy security french system
- Presence of an evolutionary cancer
- any evolutionary pathology classifying AIDS
- Pregnancy
- Recent lung infection (< 2 months)
- Be under protection (saving) of justice

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01207986
France | |
Makinson | |
Montpellier, France, 34 |
Principal Investigator: | Alain Makinson | University Hospital, Montpellier | |
Principal Investigator: | Antoine Cheret | CHU Tourcoing | |
Principal Investigator: | Sophie Abgrall | Hospital Avicenne | |
Principal Investigator: | Pierre Delamonicca | CHU Nice | |
Principal Investigator: | Pierre Tattevin | Pontchaillou | |
Principal Investigator: | Isabelle Poizot Martin | St Marguerite Marseille | |
Principal Investigator: | Francois Raffi | Hotel Dieu Nantes | |
Principal Investigator: | Claudine Duvivier | Necker Paris | |
Principal Investigator: | David Zucman | Foch Suresnes | |
Principal Investigator: | Jean Louis Couderc | Foch Suresnes | |
Principal Investigator: | Tristan Ferry | La Croix Rousse Lyon | |
Principal Investigator: | Jean Marc Mauboussin | Nîmes, CH Caremeau |
Additional Information:
Responsible Party: | French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) |
ClinicalTrials.gov Identifier: | NCT01207986 History of Changes |
Other Study ID Numbers: |
AO 781-38 |
First Posted: | September 23, 2010 Key Record Dates |
Last Update Posted: | July 20, 2015 |
Last Verified: | July 2015 |
Additional relevant MeSH terms:
Lung Neoplasms HIV Infections Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases |
Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases |